S18327 (1-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3- phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at α1- and α2-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 1, 2000, Pages 54-66

  Millan, Mark J ^a   Brocco, Mauricette ^a   Rivet, Jean Michel ^a   Audinot, Valérie ^a   Newman Tancredi, Adrian ^a   Maiofiss, Lisa ^b   Queriaux, Sophie ^b   Despaux, Nicole ^c   Peglion, Jean Louis ^b   Dekeyne, Anne ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b INSTITUT DE RECHERCHES SERVIER   (France)

^c Psychopharmacology Department ^*

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 [4 (6 FLUORO 1,2 BENZISOXIZOL 3 YL)PIPERID 1 YL]ETHYL]3 PHENYL IMIDAZOLIN 2 ONE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; AMPHETAMINE; APOMORPHINE; CLOZAPINE; COCAINE; DIZOCILPINE; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; METHYLPHENIDATE; NEUROLEPTIC AGENT; PHENCYCLIDINE; PROLACTIN; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG;

AGGRESSION; ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; CATALEPSY; CLIMBING; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOPAMINE RECEPTOR BLOCKING; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; HEAD TWITCH; LATENT INHIBITION; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SCHIZOPHRENIA; SEROTONINERGIC TRANSMISSION; TAIL FLICK TEST; TRANQUILIZING ACTIVITY;

EID: 0033970947     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. 1-Noradrenergic receptor stimulation impairs prefrontal cortical cognitive function. Biol Psychiatry 45:26-31.
2. Arnt J and Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63-101.
3. Bakshi VP and Geyer MA (1997) Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist. J Pharmacol Exp Ther 283:665-674.
4. Berthold CW, Gonzales RA and Moerschbaecher JM (1992) Prazosin attenuates the effects of cocaine on motor activity but not on schedule-controlled behavior in the rat. Pharmacol Biochem Behav 43:111-115.
5. Brocco M, Gobert A, Bervoets K and Millan MJ (1999) Influence of S 18327, clozapine and other antipsychotics on dizocilpine (DIZ)-induced spontaneous tail-flicks (STF) in rats in relation to their actions at multiple monoaminergic receptors. Behav Pharmacol 10:S13.
6. Brunello N, Masotto C, Steardo L, Markstein R and Racagni G (1995) New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13:177-213.
7. 2-Adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat. Psychopharmacology 124:347-354.
8. Carasso BS, Bakshi VP and Geyer MA (1998) Disruption in prepulse inhibition after alpha-1 adrenoceptor stimulation in rats. Neuropharmacology 37:401-404.
9. Cunningham-Owens DC (1996) Adverse effects of antipsychotic agents: do newer agents offer advantages? Drugs 51:895-930.
10. Darracq L, Blanc G, Glowinski J and Tassin JP (1998) Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of D-amphetamine. J Neurosci 18:2729-2739.
11. Dekeyne A, Audinot V, Schreiber R, Monneyron S and Millan MJ (1998) Influence of selective antagonists at dopamine D2, D3 and D4 receptors on latent inhibition (LI) in the rat. Am Soc Neurosci Abstr 24:1741.
12. Eison AS and Eison MS (1994) Serotonergic mechanisms in anxiety. Prog NeuroPsychopharmacol Biol Psychiatr 18:47-62.
13. Faustman WO, Bardgett M, Faull KF, Pfefferbaum A and Csernansky JG (1999) Cerebrospinal fluid glutamate inversely correlates with positive symptom severity in unmedicated male schizophrenic/schizoaffective patients. Biol Psychiatry 45: 68-75.
14. Friedman JI, Tempori H and Davis KL (1999) Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 45:1-16.
15. 1/D2 antagonism in extrapyramidal functions. Br J Psychiatry 160 (Suppl 17):34-37.
16. Gordon AD (1987) A review of hierarchical classification. J R Stat Soc 150:119-137.
17. Goudie AJ and Taylor A (1998) Comparative characterisation of the discriminative stimulus properties of clozapine and other antipsychotics in rats. Psychopharmacology 135:392-400.
18. 2-Adrenoreceptor antagonism may contribute to the atypical properties of risperidone: Experimental support for the Nutt case. J Psychopharmacol 9:281-283.
19. Hiramatsu M, Cho AK and Nabeshisma T (1989) Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. Eur J Pharmacol 166:359-366.
20. Josselin SA, Miller R and Beninger RJ (1997) Behavioural effects of clozapine and dopamine receptor subtypes. Neurosci Biobehav Rev 21:531-558.
21. 2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clopazine, in the rat. Br J Pharmacol 124:1550-1556.
22. Kenakin T (1997) Pharmacologic Analysis of Drug-Receptor Interaction. Lippincott-Raven, Philadelphia.
23. Lahoste GJ, Swanson JM, Wigal SB, Glabe C, Wigal T, King HN and Kennedy JL (1996) Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry 1:121-124.
24. 3 dopamine receptor: Neurobiology and potential clinical relevance. Pharmacol Rev 49:231-252.
25. Lieberman JA, Mailman RB, Duncan G, Sitich L, Chakos M, Nichols DE and Kraus JE (1998) Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry 44:1099-1117.
26. 1A agonists. Behavioural Pharmacol 5:42-51.
27. Martin P, Waters N, Waters S, Carlsson A and Carlsson ML (1997) MK-801-induced hyperlocomotion: Differential effects of MDL 100,907, SDZ PSD 958 and raclopride. Eur J Pharmacol 335:107-116.
28. Mathé JM, Nomikos GG, Hildebrand BE, Hertel P and Svensson TH (1996) Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur J Pharmacol 309:1-11.
29. Maurel-Rémy S, Bervoets K and Millan MJ (1995) Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors. Eur J Pharmacol 280:R9-R11.
30. 2A receptors in the nucleus accumbens. Am Soc Neurosci Abstr 24:1741.
31. McCormick DA and Pape HC (1995) Noradrenergic and serotonergic modulation of a hyperpolarization-activated cation current in thalamic relay neurons. J Physiol 431:319-342.
32. Meltzer HY (1995) Atypical antipsychotic drugs, in Psychopharmacology: The Fourth Generation of Progress (Bloom FE and Kupfer DJ eds) pp 1277-1286, Raven Press, New York.
33. Meltzer LT, Christoffersen CLs and Serpa KA (1997) Modulation of dopamine neuronal activity by glutamate receptor subtypes. Neurosci Biobehav Rev 21:511-518.
34. Michal P, Lysikova M, El-Fakahany EE and Tucek S (1999) Clozapine interaction with the M2 and M4 subtypes of muscarinic receptors. Eur J Pharmacol 376:119-125.
35. Millan MJ (1991) Antagonists at the NMDA recognition site and blockers of the associated ion channel induce spontaneous tail-flicks in the rat. Eur J Pharmacol 203:315-318.
36. 1A agonist properties. III. Anxiolytic actions in comparison with clozapine and haloperidol. J Pharmacol Exp Ther 288:1002-1014.
37. 4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridme) and raclopride. J Pharmacol Exp Ther 287: 167-186.
38. 1A agonist properties. II. Functional profile in comparison to clozapine and haloperidol. J Pharmacol Exp Ther 286:1356-1373.
39. 1A agonist properties. IV. A drug discrimination comparison with clozapine. J Pharmacol Exp Ther 289:427-436.
40. 2 antagonism. Br J Pharmacol 120:251P.
41. 20 receptor subtypes in the two types of fear generated by the elevated T-maze. Pharmacol Biochem Behav 58:1051-1057.
42. Morari M, Marti M, Sbrenna S, Fuxe K, Bianchi C and Beani L (1998) Reciprocal dopamine-glutamate modulation of release in the basal ganglia. Neurochem Int 33:383-397.
43. 2 antagonist MDL 100,907 on latent inhibition in the rat. Behav Pharmacol 5:120-121.
44. 2A receptor antagonists block MK-801-induced stereotypy and hyperlocomotion. Eur J Pharmacol 358:111-116.
45. 2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics? J Psychopharmacol 8:193-195.
46. Ögren SO and Goldstein M (1994) Phencyclidine and dizocilpine-induced hyperlocomotion are differentially mediated. Neuropharmacology 11:167-177.
47. Olianas MC, Maullu C and Onali, P (1997) Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor. Br J Pharmacol 122:401-408.
48. Prinssen EPM, Ellenbrock BA and Cools AR (1994) Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. Eur J Pharmacol 262:167-170.
49. 4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology 120:365-368.
50. 1A agonists. J Pharmacol Exp Ther 273:101-112.
51. 2-adrenoceptor antagonist idazoxan on mood, memory and attention in normal volunteers. J Psychopharmacol 6:376-381.
52. Sokoloff BP (1998) Expression of NMDAR1, GluR1. GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of "neuroleptic-free" schizophrenics: Evidence on reversible up-regulation by typical neuroleptics. J Neurochem 71: 2454-2464.
53. Steinpreis RE (1996) The behavioral and neurochemical effects of phencyclidine in humans and animals: Some implications for modeling psychosis. Behav Brain Res 74:45-55.
54. Stutzmann JM, Eon B, Darche F, Lucas M, Rataud J, Piot O, Blanchard JC and Laduron PM (1991) Are 5-HT2 antagonists endowed with anxiolytic properties in rodents? Neurosci Lett 128:4-8.
55. Tallman JF (1997) NGD 94-1: A specific dopamine-4-receptor antagonist. Adv Pharmacol 42:490-492.
56. Ward JH (1963) Hierarchical grouping to optimize an objective function. J Am Stat Assoc 58:236-244.
57. Weiner I and Feldon J (1997) The switching model of latent inhibition: An update of neural substrates. Behav Brain Res 88:11-25.
58. Wiley JL, Compton AD and Porter JH (1993) Effects of four antipsychotics on punished responding in rats. Pharmacol Biochem Behav 45:263-267.
59. 2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther 282:699-706.
60. 4 receptor ligands: Relation to antipsychotic action. Eur J Pharmacol 351:273-286.
61. Wirsching WC, Marder SR, Van Putten T and Ames D (1995) Acute treatment of schizophrenia, in Psychopharmacology: The Fourth Generation of Progress (Bloom FE and Kupfer DJ eds) pp 1259-1266, Raven Press, New York.
62. 4 receptor agonist. Eur J Pharmacol 269:R1-R2.